Pricing Log in Create free account
Friday 6 November 2026 Export CGC’s income statement to Excel — free account

Canopy Growth Corporation

CGC Healthcare Drug Manufacturers Specialty & Generic

Canopy Growth Corporation’s revenue for fiscal 2026 (year ended March 2026) was $206.0 million, up 6.55% from fiscal 2025.

Revenue
+12.4%
EPS
+87.5%
Free cash flow
−117.6%
Total debt
−18.7%

Quarter to June 2026, against a year earlier

0.68 0.07 −9.33%
Market cap
$283.5M
P/E
0.0×
Fwd P/E
−6.4×
Dividend yield
—
F-score
5/9
Altman Z
−13.21
Beneish M
−3.49
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Sold, $m 0.39
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell 2 — 1 4 — — 7 — 2 5 — —
Insider Ownership 1.20%

Capital & Financial Ratios $m

Size
Market Cap 283.50
Revenue ttm 212.47
Net income ttm (170.80)
Free cash flow ttm (60.22)
Net debt Q (73.30)
Valuation
P/E 0.00
Forward P/E (6.41) (negative: loss-making)
Price / sales 1.35
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.58
Financial health
Current ratio Q 3.04 (at or above 1.5: strong)
Debt / equity Q 0.35 (at or below 0.5: strong)
Interest coverage Q (2.03)
Growth
Revenue growth Q +12.41% (above 0%: growing)
Operating income growth Q +2.37% (above 0%: growing)
EPS, this year +83.53% (at or above 15%: strong)
EPS, next year A +18.40% (at or above 15%: strong)
Revenue, next year A +15.62% (at or above 10%: strong)
EPS, past 5 yrs —
EPS, next 5 yrs A +52.69% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.0×, against a ten-year median of 5.2×; over the ten years it ranged from 0.9× in 2026 to 63.1× in 2019.
P/S against its own 10 years 12.14%
10-year low 10-year high
P/B against its own 10 years 9.15%
10-year low 10-year high
EV/Sales against its own 10 years 1.57%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2024 2025 2026 Q'26
Cash 156 99 268 247
Receivables 38 38 26 31
Inventory 57 69 80 78
Other — — — —
275 212 383 366
2024 2025 2026 Q'26
Payables 21 19 25 21
ST’ Debt 77 3 12 21
Other 36 18 47 45
174 68 115 120

Compound Annual Growth %

10y 5y 3y
Sales 35.59% (13.04%) (12.24%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 18.08% (28.18%) (4.24%)

Earnings Trends EPS, adjusted, against the consensus

Q1 FY26 Estimate −0.04 Actual −0.02

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q2 FY26 −0.11 −0.01 Beat by 0.10
Q3 FY26 −0.03 −0.10 Miss by 0.07
Q4 FY26 −0.06 −0.17 Miss by 0.11
Q1 FY26 −0.04 −0.02 Beat by 0.02
Q2 FY26 −0.02 — Reports 6 November 2026

EPS $

Jun Sep Dec Mar Year
’26 (0.02) — — — —
’26 (0.16) 0.00 (0.13) (0.29) (0.64)
’25 (1.17) (1.08) (0.79) (1.00) (4.00)
’24 (0.50) (3.20) (1.92) (0.76) (6.52)
’23 (41.00) (3.60) (4.00) (9.50) (53.50)
’22 6.80 (0.20) (2.20) (11.50) (6.20)
’21 (2.20) (0.70) (18.60) (14.60) (35.60)
Fiscal quarters ending in the months shown.

Revenue $m

Jun Sep Dec Mar Year
’26 59 — — — —
’26 52 48 53 52 206
’25 48 46 53 45 193
’24 81 52 58 30 220
’23 86 90 75 54 305
’22 111 104 112 88 415
’21 80 102 117 116 414
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Jun Sep Dec Mar Year
’26 (18) — — — —
’26 (7) (13) (12) (14) (46)
’25 (38) (40) (17) (24) (119)
’24 (111) (59) (21) (18) (209)
’23 (110) (100) (98) (114) (422)
’22 (135) (65) (133) (103) (435)
’21 (86) (125) (72) (71) (353)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Jun Sep Dec Mar Year
’26 (19) — — — —
’26 (9) (14) (13) (14) (50)
’25 (37) (41) (18) (27) (124)
’24 (50) (8) (22) (17) (98)
’23 (112) (93) (100) (114) (419)
’22 (152) (76) (116) (107) (452)
’21 (132) (138) (86) (80) (436)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to March

Ten-year view Analyst estimates Powerpack
Group Line 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 TTM Jun ’26 Trend 10 yrs 2027e 2028e 2029e Next 3/yr
Income, $m
Income, $m Revenue 76 139 201 300 414 415 305 220 193 206 212 +11.7% 238 257 269 +9.3%
Gross margin, % 37.65 41.62 33.64 (7.95) 12.25 (37.10) (25.85) 27.22 29.56 24.48 25.16 (13.2) pt
EBT (13) (41) (501) (1,135) (1,276) (263) (2,507) (349) (429) (190) (171) +34.7%
EBT margin, % (17.07) (29.48) (248.82) (378.43) (308.05) (63.31) (822.61) (158.63) (221.94) (92.37) (80.52) (75.3) pt
Net income (13) (42) (511) (1,043) (1,266) (256) (2,504) (359) (434) (190) (171) +35.1%
Per share, $
Per share, $ Revenue 6.40 7.84 7.54 8.61 11.15 10.61 6.57 2.95 1.80 0.69 0.50 (21.9%)
Earnings (1.10) (3.10) (19.30) (28.30) (35.60) (6.20) (53.50) (6.52) (4.00) (0.64) (0.44) (5.8%)
Cash flow (1.73) (3.59) (14.86) (16.69) (9.50) (11.13) (9.10) (2.79) (1.11) (0.15) (0.13) (23.5%)
Capex (1.89) (7.84) (19.49) (15.59) (2.24) (0.42) 0.05 1.49 (0.04) (0.01) (0.01) (41.8%)
Free cash flow (3.62) (11.42) (34.34) (32.28) (11.74) (11.55) (9.05) (1.31) (1.15) (0.17) (0.14) (28.8%)
Book value 39.36 54.71 206.67 110.34 71.10 73.28 12.40 4.96 3.26 1.69 1.18 (29.5%)
Shares, m 12 18 27 35 37 39 46 75 108 298 335 +43.0%
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
P/S 0.00 31.64 56.31 16.74 28.73 7.15 2.66 2.56 0.51 1.37 1.35 14.8
P/B 2.51 4.54 2.06 1.31 4.51 1.03 1.41 1.52 0.28 0.56 0.58 2.0
EV/Sales 0.00 29.88 42.80 12.90 27.40 7.37 3.93 3.86 1.12 0.90 1.01 13.0
EV/FCF 0.00 (20.52) (9.40) (3.44) (26.02) (6.77) (2.86) (8.69) (1.76) (3.65) (3.52) (8.3)
Cash, $m
Cash, $m Operating cash flow (21) (64) (397) (581) (353) (435) (422) (209) (119) (46) (57) +9.4%
Capex (22) (139) (520) (543) (83) (17) 2 111 (5) (4) (3) (16.8%)
Free cash flow (43) (203) (917) (1,124) (436) (452) (419) (98) (124) (50) (60) +1.8%
Balance, $m
Balance, $m Working capital 122 304 3,550 1,612 1,936 1,216 207 101 144 269 245 +9.2%
Net debt (70) (245) (2,720) (1,152) (551) 93 388 286 119 (99) (73) +3.9%
Shareholders’ equity 468 970 5,518 3,840 2,642 2,868 575 371 350 505 497 +0.8%
Returns, %
Returns, % ROA (4.90) (6.71) (13.44) (16.82) (25.61) (5.00) (78.42) (34.69) (52.96) (25.90) (23.54) (21.0) pt
ROIC (1.82) (5.63) (9.82) (29.17) (28.17) (18.23) (139.89) (16.12) (11.21) (18.00) (17.19) (16.2) pt
ROE (4.49) (7.63) (16.10) (21.23) (40.80) (8.75) (144.08) (103.01) (119.21) (44.51) (40.14) (40.0) pt
People
People Employees 546 1,033 3,200 4,434 3,259 3,151 1,621 1,029 960 1,128 — +8.4%
Revenue/emp, $m 0.14 0.13 0.06 0.07 0.13 0.13 0.19 0.21 0.20 0.18 — +3.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Canopy Growth Corporation vs peers in Drug Manufacturers Specialty & Generic (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TLRY Tilray Brands, Inc. $415.3M — (loss-making) — (loss-making) +22.74% (above 0%: growing) n/m −159.66% (below 0%: shrinking) 30.14% (9.35%) Compare
KMDA Kamada Ltd. $396.3M 18.1× — (loss-making) +22.72% (above 0%: growing) +23.08% (above 0%: growing) +165.71% (above 0%: growing) 40.91% 17.32% Compare
ACB Aurora Cannabis Inc. $341.2M — (loss-making) — (loss-making) −31.15% (below 0%: shrinking) n/m −293.56% (below 0%: shrinking) 52.73% (12.92%) Compare
EBS Emergent Biosolutions Inc. $300.8M — (loss-making) — (loss-making) −52.40% (below 0%: shrinking) n/m +1,892.98% (above 0%: growing) 26.55% (33.91%) Compare
CGC Canopy Growth Corporation $283.5M — (loss-making) — (loss-making) +12.41% (above 0%: growing) n/m −117.60% (below 0%: shrinking) 27.40% (27.24%)
ANIK Anika Therapeutics Inc. $258.7M — (loss-making) 599× +15.56% (above 0%: growing) n/m +61.58% (above 0%: growing) 65.15% 9.06% Compare
BIOA BioAge Labs, Inc. $254.3M — (loss-making) — (loss-making) −85.49% (below 0%: shrinking) n/m −92.81% (below 0%: shrinking) 100.00% (12,554.03%) Compare
LFCR Lifecore Biomedical, Inc. $242.6M — (loss-making) — (loss-making) −18.60% (below 0%: shrinking) n/m +27,684.00% (above 0%: growing) 26.96% (3.53%) Compare
SIGA Siga Technologies Inc. $213.4M — (loss-making) 60.8× −49.45% (below 0%: shrinking) −66.00% (below 0%: shrinking) −75.95% (below 0%: shrinking) 57.17% 33.91% Compare
Median of peers $279.7M — — −24.87% — −7.18% 46.82% (6.44%)

All 84 Drug Manufacturers Specialty & Generic stocks →

Pay and ownership Proxy statement filed 7 August 2026

Ownership

Directors and executive officers, together less than 1%
CBI Group 5.80%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Canopy Growth Corporation (CGC) Latest News

29 Oct

Impact 3 · · Zacks

27 Oct

Impact 3 ·

26 Oct

Impact 4 · · Business Wire

23 Oct

Impact 3 · · MarketBeat

22 Oct

Impact 4 · · Business Wire

21 Oct

Impact 3 · · Zacks

18 Oct

Impact 3 · · The Motley Fool

14 Oct

Impact 3 · · Zacks
Impact 3 · · Zacks

13 Oct

Impact 4 · · Business Wire

8 Oct

Impact 3 · · 24/7 Wall St.

7 Oct

Impact 3 · · Zacks

6 Oct

Impact 3 · · The Motley Fool

1 Oct

Impact 3 · · Zacks
Impact 3 ·

30 Sep

Impact 3 · · The Motley Fool
Impact 3 · · Zacks

28 Sep

Impact 4 · · Business Wire

25 Sep

Impact 3 · · Zacks

23 Sep

Impact 3 · · Zacks
Impact 3 · · The Motley Fool

22 Sep

Impact 4 · · InvestorsHub
Impact 3 · · Business Wire

14 Sep

Impact 3 · · The Motley Fool

8 Sep

Impact 3 ·

5 Sep

Impact 3 · · The Motley Fool

31 Aug

Impact 3 · · Trefis

14 Aug

Impact 4 · · The Motley Fool transcript
Impact 3 ·

13 Aug

Impact 4 · · The Motley Fool
stockrow.com/CGC · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com